Once viewed as an experimental approach reserved for niche therapies, direct-to-patient (DTP) drug distribution is rapidly becoming one of the most consequential strategic shifts in modern pharmaceuticals.

Driven by a convergence of digital maturity, policy pressure, and patient demand for transparency, manufacturers are increasingly cutting out the intermediaries that have long defined how drugs move from factory floor to medicine cabinet. But as more companies launch DTP programs, the industry is confronting an uncomfortable reality: the opportunity is real, but so are the risks.

What is driving the shift to direct-to-patient distribution?

The momentum behind DTP has been building for years, but several forces have accelerated its arrival as a mainstream strategy. The Trump administration's executive order on healthcare affordability has renewed pressure on manufacturers to demonstrate pricing transparency and expand access, particularly for high-cost therapies. Meanwhile, the digital infrastructure required to support direct fulfillment such as, telehealth integration, e-prescribing, and real-time benefit verification, has matured to the point where end-to-end DTP programs are operationally viable at scale.

In a conversation with Pharmaceutical Executive, CaryHealth CEO Areo Nazari framed the shift in terms of structural leverage. "It opens up the ability for the government to work directly with pharma companies and negotiate prices, which changes the entire pricing equation," he said. "It also gives pharma companies more leverage by allowing them to optimize pricing efficiency and cut out middlemen such as wholesalers or, in some cases, PBMs."

According to Nazari, that efficiency has the ability to translate into tangible benefits for patients, including lower costs, faster access, and a more direct connection to the manufacturer. "Patients now have the ability to interact directly with pharma companies, and that's mutually beneficial," he says. "It's not applicable to every therapeutic area, but for chronic conditions and oral medications, it's a real opportunity."

How are DTP models reshaping the pharma supply chain?

The traditional pharmaceutical supply chain is built on layers, manufacturers sell to wholesalers, wholesalers distribute to pharmacies, pharmacies dispense to patients, and pharmacy benefit managers negotiate somewhere in between. DTP compresses or eliminates many of those layers, and the implications for pricing power, data ownership, and brand relationships are significant.

Nazari describes the dynamic similarly to a transformation that has already reshaped another major industry. "Much like in media, Netflix controls the content and now goes directly to consumers," he tells Pharm Exec. "We're seeing the same in pharma, where companies own the molecules and now want to control the patient experience."

The pharma sector, he argues, is witnessing what amounts to a "Netflix-like moment" for drug manufacturers, one where ownership of the end-to-end relationship, not just the product, becomes the source of competitive advantage.

That shift also unlocks a category of data that has historically been invisible to manufacturers. Each step in the patient journey, from benefit verification to prior authorization, all the way to fulfillment, adherence generates insights that integrated DTP platforms can capture in real time.

For commercial and market access teams, this represents a fundamental change in how brands are managed post-launch. "Working directly with government or self-insured employers just makes sense," Nazari says. "The fewer intermediaries involved, the more efficient and transparent the process becomes."

What are the risks of first-generation DTP programs?

Despite the strategic appeal, many early DTP programs have struggled to deliver on its promise. The core problem, according to industry observers, is architectural. Rather than building integrated platforms from the ground up, manufacturers have frequently assembled DTP capabilities by bolting together disconnected vendor solutions, one for telehealth, another for pharmacy, a third for patient engagement and hoping the pieces communicate effectively.

They often don't.

According to analysis from CaryHealth, first-generation DTP programs have seen drop-off rates of 30% to 40% during patient handoffs, not because patients reject therapy, but because fragmented systems create friction that drives abandonment.

"Historically, pharma programs were fragmented, you had one vendor for telehealth, another for pharmacy, and yet another for engagement," Nazari says. "What we're seeing now is the recognition that patients want a unified, seamless experience from start to finish."

Those drop-off rates carry real commercial consequences. For manufacturers, they represent lost visibility into the patient journey, diminished return on investment, and continued dependence on the third parties they set out to bypass. The fix, Nazari argues, is purpose-built integration, a single data layer connecting every function from e-prescribing to fulfillment to analytics, rather than incremental additions to existing infrastructure.

How is compliance shaping DTP program design?

As DTP programs gain scale, questions of data security, patient privacy, and regulatory compliance move from afterthought to foundational design requirement. The sensitivity of patient data flowing through DTP ecosystems creates significant obligations under HIPAA and an evolving patchwork of state-level pharmacy and licensure requirements.

Nazari acknowledged the tension directly, noting that manufacturers' appetite for patient data is not inherently at odds with compliance, but must be carefully managed. "Pharma obviously wants as much data as possible, and often for good reason, to benefit the patient," he says. "But attorneys and compliance officers are always evaluating: What are the limits? What does the [business associate agreement] cover? How should these programs be structured? Ensuring it's done in a compliant way will always be top of mind."

The operational model that has emerged in leading DTP programs pairs intelligent automation with built-in clinical guardrails. Automated benefit verification and prior authorization reduce time to fill, while rule engines flag exceptions or contraindications for pharmacist review before fulfillment.

"The human touch remains where it matters most in clinical decision-making and pharmacist oversight," he explains. "But everything else, front-end and back end, is built for speed, accuracy, and scale."

What role does the regulatory environment play in DTP's growth?

The policy context surrounding DTP is being shaped as much by what regulators are not doing as by what they are. The Trump administration's focus on drug pricing has created a favorable environment for manufacturer-direct models, but the parallel push against DTC prescription drug advertising has introduced uncertainty about how manufacturers can reach and engage patients outside traditional channels.

In September 2025, President Trump issued a statement calling on FDA to more strictly enforce existing DTC advertising regulations, arguing that drug advertisements were providing patients with insufficient information. HHS Secretary Robert F. Kennedy Jr. amplified the concern, stating, "Pharmaceutical ads hooked this country on prescription drugs. We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America's chronic disease epidemic."

But Dan Troy, currently a managing director and expert witness at BRG and former lead counsel at FDA under previous administrations, told Pharmaceutical Executive that significant regulatory action in this space remains unlikely.

"There are constitutional limits on what government can do here," Troy said. "Although the mandate from leadership called to ban DTC ads on TV and social media, that's just not possible given the First Amendment."

Troy added that the administration appears to have recognized those constraints internally. "My sources tell me that the idea of a notice of proposed rulemaking on DTC ads to try and close the ostensible loophole is dead," he said. "This administration, especially at FDA, they're not doing rulemaking."

He also cautioned against reading the administration's rhetoric as a reliable signal for formal regulatory change. "I expect that they'll still continue to send out somewhat more aggressive warning letters and untitled letters than had been the case for the previous 10-to-15 years, but I don't see a guidance or a regulation on the horizon, no matter who's in charge of FDA."

What is the future of direct-to-patient models?

The structural forces underpinning DTP models such as, PBM scrutiny, digital ecosystem maturity, and government negotiation pressure are not temporary. Nazari argues they add up to something durable.

"There are pharmacy deserts emerging across the country, PBMs are under pressure, and digital ecosystems have matured," he says. "Add government negotiation and employer partnerships, and you've got all the ingredients for a new era in pharma."

He is careful to note that DTP will not be the right model for every therapeutic category, as high-complexity biologics, therapies requiring cold-chain logistics, or drugs delivered in clinical settings will likely continue moving through traditional distribution channels. But for oral medications, chronic disease management, and therapies where adherence and patient experience drive outcomes, DTP offers a compelling alternative and one that manufacturers are increasingly unwilling to cede to retail intermediaries.

"At the end of the day, it's about meeting patients where they are. Giving them options, whether that's home delivery, same-day fulfillment, or pickup at their local pharmacy. The future of pharma will be defined by how well we customize the experience while keeping it compliant, connected, and centered on the patient, " says Nazari.